NCT07913685CompletedPhase 4
The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
The Effect of Liraglutide as an Adjunct to Dietary Intervention on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The aim of the study is to evaluate the effect of a 12-week liraglutide treatment as an addition to dietary intervention in comparison to dietary intervention alone on body weight, body composition, ectopic lipid accumulation and insulin sensitivity in subjects with overweight or obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 83 (actual)
- First submitted
- 28 Oct 2026
- Start date
- 5 Apr 2023
- Primary completion date
- 9 Sept 2025
- Lead sponsor
- Medical University of Bialystok
- Diseases
- Obesity
- NCT number
- NCT07913685
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 83
- From 5 Apr 2023 to the primary completion date, 9 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- diabetes diagnosed previously or during screening
- current use of anticoagulative and/or antiplatelet medications
- use of steroids in the past 12 months
- pharmacologic treatment of obesity in the previous 3 months
- alcohol and/or drug abuse
- infections in the previous month - temporary exclusion
Other illness
- chronic inflammatory diseases
- coronary syndromes and heart failure
- malignant neoplasm - current or in the past
- psychiatric disorders and/or current use of antidepressive or antipsychotic medications
- chronic kidney or liver failure
- polycystic ovary syndrome and/or other hormonal disorders, oral contraception, hormone replacement therapy
Lab values
- the use of glucose-, weight- and lipid-lowering medications or anti-inflammatory drugs within the past 3 months
Other
- uncontrolled hyperthyroidism or hypothyroidism
- current smoking
- regular high-intensity physical activity
- specific dietary requirements impossible to fit into study plan
- pregnancy and/or breastfeeding
Who the study is looking for
- age between 18 and 60 years (both inclusive)
- body mass index ≥27 kg/m2
- informed oral and written consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Bialystok Coordinator of this site? Confirm its status | Bialystok | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.